文献速递垂体与肾上腺疾病甲状腺疾病性腺与生殖内分泌

超越MEN1:何时考虑MEN4?法国5600例患者回顾性研究及文献综述

Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该研究在法国5600例疑似MEN1患者中评估MEN4患病率并描述其表型,发现4例(0.07%)携带CDKN1B 4/5类变异,结合文献29例与66例匹配MEN1患者比较,MEN4患者神经内分泌肿瘤发生率更低、原发性甲状旁腺功能亢进诊断年龄更晚,提示MEN4表型较MEN1更轻且更晚。

要点

  • 在5600例疑似MEN1患者中,CDKN1B 4/5类变异检出率为0.07%(4例)。
  • MEN4患者主要表现为原发性甲状旁腺功能亢进和垂体腺瘤,神经内分泌肿瘤罕见。
  • 与匹配MEN1患者相比,MEN4患者神经内分泌肿瘤发生率更低、原发性甲状旁腺功能亢进诊断年龄更晚。

核心结论

  • MEN4患病率低,原发性甲状旁腺功能亢进和垂体腺瘤为主要相关病变,神经内分泌肿瘤罕见,结果提示MEN4表型较MEN1更轻且更晚。

研究设计与样本

  • 回顾性观察性全国性研究,纳入2015年至2022年法国神经内分泌肿瘤肿瘤遗传学网络实验室因疑似MEN1行胚系基因检测发现CDKN1B 3/4/5类变异的全部成年患者,并进行文献叙述性综述及变异分类再评估。

主要发现

  • 从5600例疑似MEN1患者中分析发现4例携带CDKN1B 4/5类变异(0.07%),表现为多发性十二指肠神经内分泌肿瘤、原发性甲状旁腺功能亢进和肾上腺结节、孤立性原发性甲状旁腺功能亢进、原发性甲状旁腺功能亢进以及胰腺神经内分泌肿瘤。
  • 文献中列出29例携带CDKN1B 4/5类变异的患者。
  • 与66例匹配的MEN1患者相比,MEN4患者神经内分泌肿瘤发生率更低,原发性甲状旁腺功能亢进诊断年龄更晚。

关键数值与推荐

  • CDKN1B 4/5类变异在5600例疑似MEN1患者中检出4例(0.07%)。
  • 文献汇总CDKN1B 4/5类变异患者29例。
  • 与66例匹配MEN1患者比较,MEN4患者神经内分泌肿瘤发生率更低、原发性甲状旁腺功能亢进诊断年龄更晚。

临床怎么用

  • 作者认为观察结果有助于改善MEN4家族的遗传咨询和管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Germline CDKN1B variants predispose patients to multiple endocrine neoplasia type 4 (MEN4), a rare MEN1-like syndrome, with <100 reported cases since its discovery in 2006. Although CDKN1B mutations are frequently suggested to explain cases of genetically negative MEN1, the prevalence and phenotype of MEN4 patients is poorly known, and genetic counseling is unclear. OBJECTIVE: To evaluate the prevalence of MEN4 in MEN1-suspected patients and characterize the phenotype of MEN4 patients. DESIGN: Retrospective observational nationwide study. Narrative review of literature and variant class reassessment. PATIENTS: We included all adult patients with class 3/4/5 CDKN1B variants identified by the laboratories from the French Oncogenetic Network on Neuroendocrine Tumors network between 2015 and 2022 through germline genetic testing for MEN1 suspicion. After class reassessment, we compared the phenotype of symptomatic patients with class 4/5 CDKN1B variants (ie, with genetically confirmed MEN4 diagnosis) in our series and in literature with 66 matched MEN1 patients from the UMD-MEN1 database. RESULTS: From 5600 MEN1-suspected patients analyzed, 4 with class 4/5 CDKN1B variant were found (0.07%). They presented with multiple duodenal NET, primary hyperparathyroidism (PHPT) and adrenal nodule, isolated PHPT, PHPT, and pancreatic neuroendocrine tumor. We listed 29 patients with CDKN1B class 4/5 variants from the literature. Compared with matched MEN1 patients, MEN4 patients presented lower NET incidence and older age at PHPT diagnosis. CONCLUSION: The prevalence of MEN4 is low. PHPT and pituitary adenoma represent the main associated lesions, NETs are rare. Our results suggest a milder and later phenotype than in MEN1. Our observations will help to improve genetic counseling and management of MEN4 families.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chevalier B, Coppin L, Romanet P, et al. Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review. J Clin Endocrinol Metab. 2024. PMID: 38288531. doi:10.1210/clinem/dgae055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。